Imeglimin hydrochloride

Research use only, not for human use.

Imeglimin hydrochloride prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration.

Imeglimin hydrochloride prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration.(In Vitro):Preincubation with Imeglimin (10?mM for 4?h or 100?μM for 24?h) also fully prevented tert-butylhydroperoxide (tBH)-induced cell death.(In Vivo):Imeglimin (200 mg/kg b.i.d. by oral gavage during the last 6 weeks of HFHSD feeding) significantly decreases hyperglycemia, and restores normal glucose tolerance.

Preincubation with Imeglimin (10?mM for 4?h or 100?μM for 24?h) also fully prevented tert-butylhydroperoxide (tBH)-induced cell death. Cell Viability Assay Cell Line:Human endothelial cells (HMEC-1)Concentration:100?μM and10?mM Incubation Time:100?μM for 24?h, 10?mM for 4?h Result:Prevention of cell death.

Imeglimin (200 mg/kg b.i.d. by oral gavage during the last 6 weeks of HFHSD feeding) significantly decreases hyperglycemia, and restores normal glucose tolerance. Animal Model:Male C57BL/6JOlaHsd mice (4 weeks old)Dosage:200 mg/kg Administration:Oral gavage; b.i.d.; 6 weeks Result:A slight decrease in body weight and food intake associated with some diarrhea was observed but only during the first few days of treatment.

EMD 387008 hydrochloride

Others

Other Targets

mitochondrial phospholipid

Metabolic Disease

Type 2 diabetes mellitus

775351-61-6

191.66

C6H14ClN5

>98% (HPLC)

DMSO:25 mg/mL (130.44 mM)

C[C@@H]1N=C(N)NC(N(C)C)=N1.Cl

——

(-20℃)

With Ice Pack

≥ 2 years